Filtered By:
Management: Hospitals
Vaccination: Veterinary Vaccinations
This page shows you your search results in order of date.
Order by Relevance | Date
Total 37 results found since Jan 2013.
New RYBREVANT ® (amivantamab-vmjw) Data Showed Long-Term Clinical Response and Safety in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations Who Have Failed Prior Platinum-Based Chemotherapy
COPENHAGEN, DENMARK, March 29, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new long-term data from the CHRYSALIS study evaluating RYBREVANT® (amivantamab-vmjw) in patients with advanced non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease progressed on prior platinum-based chemotherapy.1 Data from the study showed long-term response and safety in this population and were presented in an oral presentation at the 2023 European Lung Cancer Congress (ELCC) (Abstract #779).1In the analysis of the CHRYSALIS study, inve...
Source: Johnson and Johnson - March 29, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Norovirus Is on the Rise. What to Know About Symptoms and Treatment
While SARS-CoV-2 has dominated headlines for the past few years, other viruses have been simmering in the background. And with most of COVID-19’s infection control measures (like mask-wearing, isolation, and physical distancing) now gone in the U.S., those viruses are starting to roar back again.
The U.S. has already seen spikes in RSV and influenza, and now norovirus cases are inching upward, according to the latest data from the U.S. Centers for Disease Control and Prevention (CDC). Unlike SARS-CoV-2, RSV, and influenza, norovirus is not a respiratory pathogen but instead causes problems in the gastrointestinal tra...
Source: TIME: Health - February 10, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthscienceclimate Public Health Source Type: news
A Look Back at 2022: Progress Towards the Treatment of Aging as a Medical Condition
At the end of 2022, we can reflect on the fact that we are steadily entering a new era of medicine, one in which mechanisms of aging are targeted rather than ignored. It is a profound change, one that will change the shape of a human life and ultimately the human condition by eliminating the greatest sources of suffering and death in the world. Year after year, we see increased funding, ongoing progress towards therapies capable of slowing aging or reversing aspects of aging, and a growing taxonomy of such potential therapies and their target mechanisms.
The view of aging in the medical community and public at large...
Source: Fight Aging! - December 30, 2022 Category: Research Authors: Reason Tags: Of Interest Source Type: blogs
Uganda Reports Worrisome Increase in Ebola Cases in Capital
KAMPALA, Uganda — Ugandan officials have reported 11 more cases of Ebola in the capital since Friday, a worrisome increase in infections just over a month after an outbreak was declared in a remote part of the East African country.
Nine more people in the Kampala metropolitan area tested positive for Ebola on Sunday, in addition to two others on Friday, Health Minister Jane Ruth Aceng said Monday.
A top World Health Organization official in Africa said last week that Uganda’s Ebola outbreak was “rapidly evolving,” describing a challenging situation for health workers.
Ugandan health authorities have...
Source: TIME: Health - October 20, 2022 Category: Consumer Health News Authors: Rodney Muhumuza/AP Tags: Uncategorized Disease healthscienceclimate wire Source Type: news
U.S. FDA Approves IMBRUVICA ® (ibrutinib) as First and Only BTKi Treatment for Pediatric Patients with Chronic Graft-Versus-Host Disease
August 24, 2022 (HORSHAM, PA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA® (ibrutinib) for the treatment of pediatric patients one year and older with chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy. This milestone marks the first pediatric indication for IMBRUVICA® and the introduction of a new oral suspension formulation for patients ages one to less than 12. IMBRUVICA® is now the first FDA-approved therapy for these younger patients who previously had no approv...
Source: Johnson and Johnson - August 24, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
The Macro View – Health, Economics, and Politics and the Big Picture. What I Am Watching Here And Abroad.
August 18, 2022 Edition-----The main issue, probably of the year, is the increasing tension across the Taiwan Strait with all sorts of worries about how conflict can be avoided and prosperity maintained at a reasonable level as tensions continue. And hopefully ease.The impact of climate change in Europe is really becoming obvious and worrying. I am not sure just how a realistic response is possible in any reasonable time.In OZ the PM has come back after a week off to have the Chinese Ambassador tell us we are a vassal and to just shut up and behave. Astonishing and serious stuff IMVHO.-----Major Issues.-----https://www.smh...
Source: Australian Health Information Technology - August 18, 2022 Category: Information Technology Authors: Dr David G More MB PhD Source Type: blogs
What to Know About the Monkeypox Drug TPOXX —And Why It ’ s So Hard to Get
Monkeypox, which federal officials declared a public health emergency on August 4, is not as contagious as the other ongoing public health emergency in the U.S.: COVID-19. Monkeypox primarily spreads through contact with infected skin lesions. Theoretically, containing monkeypox should therefore be more feasible, as long as testing, vaccines, and treatments are accessible. But in reality, the rollouts of all three approaches have faced major challenges. Getting the antiviral drug tecovirimat, also known as TPOXX, is particularly difficult.
Here’s what to know about the antiviral drug treatment TPOXX.
What is TPOXX?
T...
Source: TIME: Health - August 9, 2022 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthscienceclimate monkeypox Source Type: news
The Macro View – Health, Economics, and Politics and the Big Picture. What I Am Watching Here And Abroad.
August 04, 2022 Edition-----The war seems to grind on sadly and Pres. Biden is having a second round with COVID as unprecedented weather happens all over the US. It all feels rather like ‘the end of days’!In the UK we see an increasing chance of a third female PM being elected as the country seems to be struggling. We do need to remember however the UK remains a significant power with nuclear weapons and home-grown nuclear submarines!In OZ we have had last week working out how to progress the First Nations ‘Voice’ as we wrap up the 1st session of Parliament for the new Government. Comments welcome on how you think ...
Source: Australian Health Information Technology - August 4, 2022 Category: Information Technology Authors: Dr David G More MB PhD Source Type: blogs
New IMBRUVICA ® (ibrutinib) Data in Fixed-Duration Combination Regimen Presented at EHA 2022 Shows Deep, Durable Response at Three Years in Untreated Chronic Lymphocytic Leukemia
June 10, 2022 (VIENNA) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new and updated results from the Phase 2 CAPTIVATE study evaluating IMBRUVICA® (ibrutinib) in combination with venetoclax (I+V) as a potential fixed-duration (FD) treatment in adult patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Updated data from the FD cohort with three years of follow-up shows that I+V continues to demonstrate deep and durable responses and clinically meaningful progression-free survival (PFS) and overall survival (OS) in the first-line tre...
Source: Johnson and Johnson - June 10, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Cancer
I sometimes like to open my posts with a joke. But not this time. There isn ' t a joke for this.Mrs. Dalai has cancer.How ' s that for a kick in the ass? I am neither vain nor arrogant enough to think that I could write the ultimate treatise on dealing with a loved one ' s cancer. There are any number of engaging stories out there on Caring Bridge and the like. You don ' t want to read a tear-jerker anyway, nor do you want to endure every last boring and/or gory detail. Mrs. Dalai would be very upset with me if I shared all that. Hell, she ' s probably going to be upset with me for writing this at all. She is a very p...
Source: Dalai's PACS Blog - September 4, 2021 Category: Radiology Source Type: blogs
We Used to Have a Lyme Disease Vaccine. Are We Ready to Bring One Back?
At my animal hospital in upstate New York, an epicenter of the U.S. tick epidemic, my dog Fawn lets out a whimper as the veterinarian injects her with her annual Lyme disease shot. I roll my eyes. She doesn’t know how good she has it.
The injection means that if a tick bites her (and in rural New York, a tick always does), the creepy crawly will feast on dog blood that’s been supercharged with a Lyme bacteria-killing substance, and Lyme disease won’t be transmitted to Fawn.
I wish I could be shot up with that superpower. Currently, there is no human vaccine for Lyme disease—even though more than two...
Source: TIME: Health - June 17, 2021 Category: Consumer Health News Authors: Mandy Oaklander Tags: Uncategorized Disease feature Source Type: news
Fight Aging! Newsletter, August 24th 2020
We report that electrical stimulation (ES) stimulation of post-stroke aged rats led to an improved functional recovery of spatial long-term memory (T-maze), but not on the rotating pole or the inclined plane, both tests requiring complex sensorimotor skills. Surprisingly, ES had a detrimental effect on the asymmetric sensorimotor deficit.
Histologically, there was a robust increase in the number of doublecortin-positive cells in the dentate gyrus and SVZ of the infarcted hemisphere and the presence of a considerable number of neurons expressing tubulin beta III in the infarcted area. Among the genes that were unique...
Source: Fight Aging! - August 23, 2020 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Vaccines, Antibodies and Drug Libraries. The Possible COVID-19 Treatments Researchers Are Excited About
In early April, about four months after a new, highly infectious coronavirus was first identified in China, an international group of scientists reported encouraging results from a study of an experimental drug for treating the viral disease known as COVID-19.
It was a small study, reported in the New England Journal of Medicine, but showed that remdesivir, an unapproved drug that was originally developed to fight Ebola, helped 68% of patients with severe breathing problems due to COVID-19 to improve; 60% of those who relied on a ventilator to breathe and took the drug were able to wean themselves off the machines after 18...
Source: TIME: Health - April 14, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
All Your Coronavirus Questions, Answered
One of the worst symptoms of any plague is uncertainty—who it will strike, when it will end, why it began. Merely understanding a pandemic does not stop it, but an informed public can help curb its impact and slow its spread. It can also provide a certain ease of mind in a decidedly uneasy time. Here are some of the most frequently asked questions about the COVID-19 pandemic from TIME’s readers, along with the best and most current answers science can provide.
A note about our sourcing: While there are many, many studies underway investigating COVID-19 and SARS-CoV-19, the novel coronavirus that causes the illn...
Source: TIME: Health - April 14, 2020 Category: Consumer Health News Authors: TIME Staff Tags: Uncategorized COVID-19 Explainer Source Type: news
